CEDARHURST, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.
YogaWorks, Inc. (NasdaqGM: YOGA) A class action has commenced on behalf of shareholders in YogaWorks, Inc. who purchased shares pursuant to the IPO commenced around August 10, 2017 and closed on August 16, 2017. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: The complaint alleges that Defendants violated their disclosure obligations because the Offering Materials materially misrepresented and failed to adequately disclose the truth concerning several known trends negatively impacting YogaWorks’ business at the time of the IPO, including, inter alia: (i) declining studio profitability; (ii) the impact of increased corporate overhead; (iii) declining financial metrics that would ultimately lead to a substantial impairment charge and (iv) the conditions that led the Defendants to postpone the initial offering.
Shareholders may find more information at https://kseclaw.com/securities/yogaworks-inc/?wire=3
The Goldman Sachs Group, Inc. (NYSE: GS) A class action has commenced on behalf of shareholders in The Goldman Sachs Group, Inc. who purchased shares between February 28, 2014 and December 17, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with 1Malaysia Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably subject Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kseclaw.com/securities/the-goldman-sa...nc/?wire=3
Yangtze River Port and Logistics Limited (NASDAQGS: YRIV) A class action has commenced on behalf of shareholders in Yangtze River Port and Logistics Limited who purchased shares between February 2, 2016 and December 5, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Yangtze’s purported lease of the Wuhan Yangtze River Newport Logistics Center, the Company’s main asset, was a fabrication; (2) Yangtze’s only operating subsidiary, Wuhan Newport, was declared insolvent in China due to a number of default judgments against it; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://kseclaw.com/securities/yangtze-river-...ed/?wire=3
Alkermes plc (NASDAQGS: ALKS) A class action has commenced on behalf of shareholders in Alkermes plc who purchased shares between February 17, 2017 and November 1, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
Shareholders may find more information at https://kseclaw.com/securities/alkermes-plc/?wire=3
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT: Kuznicki Law PLLC Daniel Kuznicki, Esq. 445 Central Avenue, Suite 334 Cedarhurst, NY 11516 Email: dk@kclasslaw.com Phone: (347) 696-1134 Cell: (347) 690-0692 Fax: (347) 348-0967
